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Genz-644282, a Novel
Topoisomerase activity is crucial for initiation and elongation during DNA synthesis, for the proper separation of sister chromatids during mitosis, for RNA transcription and for illegitimate recombination events (5) (6) (7) (8) . Top1 associates preferentially with transcriptionally active genes and is thought to be involved in relaxing supercoils introduced by RNA polymerase during RNA transcription (9, 10).
Top1 produces a single strand break in DNA allowing relaxation of DNA for replication. The single strand break is then religated restoring the DNA double strands.
The Top1 reaction intermediate consists of the enzyme covalently linked to a nicked DNA molecule. This assembly is known as a "cleavable complex" (12, 13) . The Top1-targeted drugs topotecan and irinotecan and the Top2-targeted drugs doxorubicin, amsacrine, etoposide and teniposide, stabilize the covalent enzyme-DNA complex preventing religation (11) . The cytotoxicity of Top1 inhibitors is due to trapping Top1-DNA cleavage complex as opposed to inhibition of Top1 catalytic activity. The Top1-DNA cleavage complex causes DNA damage during DNA replication and transcription.
Repair of Top1-mediated DNA damage has been reviewed (2, 14) .
Camptothecin analogs topotecan and irinotecan are FDA-approved Top1-targeted drugs. In vivo, there is a chemical equilibrium between the lactone form and the E ringopened form of the camptothecins. The E ring-opened carboxylate form has less than substrates for P-gp efflux pumps and for the pump known as breast cancer resistant protein (BCRP) (16, 17) .
Bone marrow is critically sensitive to many antineoplastic agents and contributes to toxicity. Top1 inhibitors kill rapidly dividing bone marrow progenitor cells as well as tumor cells, resulting in acute reversible neutropenia and thrombocytopenia 4 to 20 days after administration (27) . Bone marrow granulocyte-macrophage-colony forming unit (CFU-GM) assays comparing the sensitivity of bone marrow cells across species are useful in predicting the blood levels of an agent that might be achieved with acceptable toxicity in patients (27) (28) (29) (30) . Generally, murine bone marrow has a lower sensitivity to Top I inhibitors than does human bone marrow. The difference in sensitivity between murine and human bone marrow progenitor cells to Top1 inhibitors may explain, in part, why curative doses/blood levels of topotecan and 9-amino-camptothecin in mice with human tumor xenografts are not achievable in patients (30) . A compound with similar bone marrow progenitor sensitivity across species may have better potential for reaching the same blood level in patients as in mice. Pessina et al (27) suggested that through use of the ratio of mouse/human CFU-GM IC 90 values and the mouse maximum tolerated dose that the human maximum tolerated dose of a compound could be predicted and the potential for achieving a therapeutic blood level in patients estimated.
Nitidine and fagaronine are benzo[c]phenanthridine alkaloids with good antitumor potency and are active Top1 inhibitors (31, 32) . Synthetic compounds of this class are as potent as camptothecin in stimulating Top1-mediated DNA cleavage using purified human Top1 and are more potent than irinotecan in many human tumor xenografts (23, 33 ). An extensive structure-activity relationship was conducted around the 
MATERIAL AND METHODS

Materials
The purity and chemical identity of Genz-644282 (8, 9-dimethoxy-5-(2-N- Topotecan, irinotecan and SN-38 were used as purchased from LKT Laboratories (St.
Paul, MN). Genz-644282 and ARC-111 were prepared as a 100 µM stock solution in D5W (5% Dextrose, aqueous, Injection USP, B. Braun Medical Inc., Irvin, CA). For cell culture, topotecan and SN-38 were prepared as 10 mM stock solutions in DMSO from Sigma (#D-5879) and dilutions for experiments prepared in RPMI/5% FBS.
Mouse Bone Marrow
Male Balb/c mice were purchased from Charles River Laboratories (Wilmington, MA) at 6-8 weeks of age and used for studies at 7-10 weeks of age. Procedures were carried out according to a protocol approved by the Institutional Animal Care and Use Committee in accordance with the Federal Animal Welfare Act (9 CFR, 1992) and were conducted in an AAALAC accredited facility.
For sterile bone marrow collection, mouse femoral and tibial shafts were flushed with sterile RPMI 1460/5% FBS with a syringe and blunt 27G needle. The resulting cellular suspension was collected into a 50 ml conical bottom tube and kept on wet ice.
Approximately 25 million cells were obtained from each mouse.
Research. 
Human Bone Marrow
Viable human bone marrow cells were purchased as frozen vials from AllCells, LLC via StemCell Technologies, (#ABM009). They were prepared with a DNase treatment (#07900, StemCell Technologies), and washed in a protocol described by the vendor in preparation for culture.
Bone Marrow CFU-GM Assay
For mouse CFU-GM assays, freshly isolated mouse bone marrow cells were cultured in MethoCult, containing the cytokines rmSCF, rmIL-3, rhIL-6 (StemCell Technologies, Vancouver, BC). For human CFU-GM assays, the culture medium used was MethoCult GF, containing the cytokines hSCF, hGM-CSF, hIL-3 (StemCell Technologies). Plates were incubated overnight at 37ºC in humidified air with 5% CO 2 . Plates were incubated with Genz-644282 at 37ºC with humidified air/5% CO 2 for 72 hrs. After the 
Human Tumor Xenografts
The efficacy of Genz-644282 was compared with standard anticancer drug Animals were assigned to treatment (n = 8-10) or control groups (n = 8-10). Compounds were prepared freshly prior to injection, with Genz-644282 was formulated in M/6 lactate, irinotecan in D5W, gemcitabine in saline, and docetaxel in ethanol, Cremophor EL and saline. The doses, schedules and routes for each compound were determined in earlier MTD studies. Genz-644282 was tested on three schedules and the most effective, non-toxic regimen was selected for further study. 
Pharmacokinetic Studies
Liquid chromatography with tandem mass spectrometry (LC-MS/MS) was used to quantitate Genz-644282 in blood, plasma and tumor tissue of nude (nu/nu) mice both naïve and bearing NCI-H460 human tumor xenografts. The pharmacokinetics of Genz-644282 were evaluated in male nude/nude mice following a single IV dose of 2.0 mg/kg administered as the free base prepared in a lactic acid-sodium lactate-water formulation.
Non-compartmental pharmacokinetic parameters were determined. Pharmacokineticphamracodynamic modeling was carried out by the method of Simeoni et al (44) .
Statistical Analysis
Concentration response data for bone marrow CFU-GM and human tumor cell line CFU were analyzed using a nonlinear curve fit based upon the equation y = a*exp(b*x). The IC50 and IC90 values and the 95% confidence interval for each compound on human and mouse bone marrow were determined by nonlinear regression analysis using SAS version 8.2. Tumor volumes were calculated using the formula (w concentrations killing 50% and 90% of the cells were readily achieved. Human and mouse bone marrow CFU-GM IC 50 's were 3-to 4-fold lower than the corresponding IC 90 's, thus the concentration response curves for these compounds are steep (FIGURE 1B). Human bone marrow CFU-GM was more sensitive to the cytotoxicity of the compounds than was mouse bone marrow CFU-GM. Genz-644282 and ARC-111 were more potent cytotoxic agents than the camptothecins, topotecan and SN-38 (irinotecan).
The ratios of the mouse and human bone marrow CFU-GM at the IC 50 and IC 90 concentrations were calculated. For the camptothecins the ratios were greater than or equal to 10 and for Genz-644282 and ARC-111 the ratios were 4 to 7. Bone marrow granulocyte-macrophage-colony forming (CFU-GM) assays comparing the toxic effects on bone marrow by investigational agents across species have been useful in predicting the blood levels that might be reached in patients compared with blood levels in preclinical efficacy and safety species (27) . Frequently, mouse bone marrow is less sensitive than human bone marrow to investigational agents allowing blood levels to be achieved in mouse preclinical efficacy testing that can not be reached in patients. The bone marrow toxicity of four Top1 inhibitors was examined (FIGURE 1B) (26) (27) (28) (29) (30) . Murine bone marrow is 4-to 28-fold less sensitive to the Top1 inhibitors 
In earlier reports, ARC-111 was shown to be an effective antitumor agent against several standard human tumor xenografts. ARC-111 was as active as irinotecan in the HCT-8 colon carcinoma and as active as topotecan or irinotecan in the SKNEP anaplastic Wilm's xenograft (23) . ARC-111 was also a very effective antitumor agent in animals bearing the SJ-BT45 medulloblastoma (34) . In subsequent studies, ARC-111 was as or more effective as an anticancer agent compared with irinotecan in the HCT116 and HT29 human colon carcinoma xenografts, docetaxel in the NCI-H460 human non-small lung carcinoma xenograft and gemcitabine in the MiaPaCa2 human pancreatic carcinoma xenograft (26) . In the current study, Genz-644282 demonstrated greater or equal antitumor efficacy as irinotecan in four human colon carcinoma xenografts, greater antitumor efficacy than dacarbazine in the human LOX IMVI melanoma xenograft, greater antitumor efficacy than irinotecan in the human 786-O renal cell carcinoma xenograft, and greater than or equal antitumor efficacy than docetaxel in two human nonsmall lung carcinoma xenografts. In an initial combination chemotherapy regimen, Genz-644282 and docetaxel together showed a modest increase in tumor response in the NCI-H460 non-small cell lung carcinoma xenograft compared with Genz-644282 as a single agent. 
field for biomarkers such as gene signatures or markers based upon protein phosphorylation levels and mRNA levels in tumor or blood samples that can identify patients most likely to benefit from treatment with a specific Top1 inhibitor.
Genz-644282 is a promising non-camptothecin Top1 inhibitor that based upon preclinical activity and safety was selected for development and is currently undergoing a Phase 1 clinical trial. 
